Concepedia

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

Yung‐Sung Yeh, Hsiang‐Lin Tsai, Ching‐Wen Huang, Jui‐Ho Wang, Yi-Wen Lin, Hsiu-Chih Tang, Yung‐Chuan Sung, Chang‐Chieh Wu, Chien-Yu Lu, Jaw‐Yuan Wang

Trials · 2016 · 24 citations · 18 references

DOIFull text

Open access

Abstract

NCT02256800 . Date of registration: 3 October 2014. Date of first patient randomized: 16 January 2015.

References

18

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.8K citations · Full text

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

J-Y Douillard, David Cunningham, AD Roth et al. · The Lancet · 2000 · 3.3K citations

, , +6

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

Leonard B. Saltz, John V. Cox, Charles D. Blanke et al. · New England Journal of Medicine · 2000 · 3K citations · Full text